Reuters reveals U.S. opens criminal probe into Cassava Sciences over Alzheimer’s research; shares drop – Reuters News Agency


Business & Finance

Reuters exclusively reported that the U.S. Justice Department has opened a criminal investigation into Cassava Sciences involving whether the biotech company manipulated research results for its experimental Alzheimer’s drug. The probe adds to scrutiny on the company from the U.S. Securities and Exchange Commission and investors after two physicians made allegations of data manipulation and misrepresentation involving research underpinning the company’s Alzheimer’s drug, called simufilam. Shares in Cassava fell more than 30% after Reuters revealed the news. 

Market Impact

Shares in Cassava fell more than 30% after Reuters revealed the news.

Article Tags

Topics of Interest: Business & Finance

Type: Reuters Best

Sectors: Equities

Regions: Americas

Countries: US

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *